OR WAIT 15 SECS
Oracle Health Sciences applications has been chosen by DreamCIS, a contract research organization in Korea. DreamCIS required a clinical trial management system to replace its legacy clinical software solution and help enable the company’s biometrics center to become an Asian clinical trial data management hub.
DreamCIS intends to use Oracle Clinical and Oracle Remote Data Capture (RDC) 4.5.3 to help meet global standards for clinical trials data management and achieve higher quality local clinical trial services. DreamCIS is the first CRO in Korea to adopt the applications.
“Oracle’s proven experience in the health sciences sector was important to us and we believe their solutions will enable us to raise our data management levels to global standards, and help us become the leader in the Asian clinical trial markets in the future,” said Hee-Joong Koh, Director, Biometrics Center, DreamCIS.
Oracle RDC 4.5.3 uses the same data model as Oracle Clinical, ensuring tight integration of data between these applications. It is also completely Web-based, with a ‘zero client footprint’ for the HTML data entry window. This enables improved global access and performance for life sciences organizations to conduct global clinical studies more cost effectively whether using traditional pen and paper, electronic data capture, or hybrid methods.
“As the number of clinical trials increases in the Korean market and throughout Asia, there is a growing need for best-in-class software applications for clinical development and drug safety,” said Neil de Crescenzo, Senior Vice President and General Manager, Oracle Health Sciences. “We are committed to helping emerging CROs like DreamCIS accelerate insights for better health and look forward to supporting their efforts to become an important hub for clinical data management in the region.”